HEAT is the acronym for the Departments of Justice and Health and Human Services’ Health Care Fraud Enforcement Action Team. And they turned up the heat on drugmaker Astra-Zeneca with a fine “to resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug Seroquel for uses not approved as safe and effective by the Food and Drug Administration.”
Comments (4)
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Paul Scott
April 28, 2010 at 10:47 amSeroquel earned A-Z $16.2 billion in the last five years alone, according to IMS health. This is surely due in part to having garnered new users for everything under the sun. I think the fine is an operating expense. Maybe your headline should be:
“Fed’s HEAT team fines A-Z 3% of Seroquel revenues over the last five years”
A drug designed for psychotic behavior — a rare condition — is among the top five most profitable drugs in the nation. Discuss.
Stephany
April 28, 2010 at 6:08 pmAhh, Seroquel the wonder drug that continues on for patent extension and profit for AstraZeneca, amidst the litigation. Re-marketed from an antipsychotic that is worthless for the “treatment” of Schizophrenia, then onto antidepressant, insomnia, public speaking fear, (stage fright),you name it–Seroquel will be and is being pushed as an all purpose drug, with a black box warning for diabetes and buried data proving AZ knew—the 45 million dollar whistleblower cash goes to an ex Pharma rep!
We live in a country that has lost it’s moral compass, and embraced corporate crime without questions.
When will the average citizen understand they are a marketing target, and this goes straight to the top of US government.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like